Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2022 16:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
December 13, 2021 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Presents New Clinical and Scientific Data at 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

- Presented data highlight mavorixafor’s ability to raise the spectrum of white blood cell counts across a broad range of diseases with or without CXCR4 mutations including Chronic Neutropenia - -...
December 11, 2021 09:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

- CXCR4 antagonism proof of concept established, with 100% overall response rate to combination treatment in frontline and refractory patients - - Median Serum IgM reductions in refractory CXCR4MUT...
December 02, 2021 06:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor

Company to present new clinical data supporting the expanded potential use of mavorixafor to treat a broad array of immunodeficiencies as well as new insights into WHIM syndrome Guest speakers...
December 01, 2021 16:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
November 10, 2021 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Participate in Stifel’s Virtual Healthcare Conference

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people...
November 04, 2021 09:01 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results

Data continue to support mavorixafor’s potential to benefit patients with WHIM syndrome, chronic neutropenia, and Waldenström’s macroglobulinemia Discovery of new prevalent WHIM variant further...
November 01, 2021 16:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
October 25, 2021 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

BOSTON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
October 19, 2021 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial

BOSTON, Oct. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...